REDWOOD CITY, Calif.--(BUSINESS WIRE)--PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced a series of new commercial partnerships and distribution agreements for its commercial typhoid vaccine Vivotif®. These agreements will ensure the global availability of Vivotif across Europe and Australia and complement the company's growing direct sales and marketing capabilities in the United States. Vivotif is currently licensed for sale in 27 countries."Typhoid is one of the most commonly delivered travel vaccines, and these agreements will ensure the availability of Vivotif to people in the European and Australian markets who are travelling to regions of the world where typhoid is endemic," said Nima Farzan, President and Chief Operating Officer of PaxVax. "Vivotif is the only oral vaccine indicated for typhoid and we look forward to working with our new distribution partners to maintain a stable global supply of this effective vaccine."
Since its acquisition of Vivotif in July 2014, PaxVax has established legal entities and commercial infrastructure in Italy, Spain and Switzerland and the United Kingdom and has partnered with the distributors Alloga (Italy, Spain and Switzerland) and Polar Speed (United Kingdom) to fulfill orders for Vivotif in these countries.
In countries where PaxVax does not maintain its own commercial operations, the company has signed agreements for the sale, marketing and distribution of Vivotif. These agreements have been put in place with Novartis in Germany, bioCSL in Australia, New Zealand and the Pacific Isles and Valneva in Denmark, Finland, Norway and Sweden. In Germany, Vivotif is sold under the brand name Typhoral®. PaxVax manufactures and assembles Vivotif for all markets in its Good Manufacturing Practice (GMP)-certified facility near Bern, Switzerland.
PaxVax has a portfolio of clinical and preclinical vaccine candidates that are supported by numerous grants, contracts, and awards from the NIH through the National Institute of Allergy and Infectious Diseases (NIAID), its Division of Acquired Immunodeficiency Syndrome (DAIDS) and its Division of Microbiology and Infectious Diseases (DMID), as well as the Wellcome Trust and the Bill and Melinda Gates Foundation. The company has raised more than $80 million from investors including Ignition Growth and Venture Partners and Blue Haven Initiative.
Vivotif is a live attenuated typhoid fever vaccine for oral administration. It is the only oral vaccine indicated for use against Salmonella typhi, the most prevalent of the typhoid fever-causing bacteria. The vaccine is indicated for adults and children over the age of six and has an excellent track record for safety, having been on the market for more than 20 years. An estimated 21 million people develop typhoid fever each year. If untreated, typhoid fever persists for three weeks to one month. Death occurs in between 10 percent and 30 percent of untreated cases. Not all recipients of Vivotif will be fully protected against typhoid fever. Vaccinated individuals should continue to take personal precautions against exposure to typhoid organisms. The most common undesirable effects reported during prior clinical trials concern the gastrointestinal tract: abdominal pain, nausea, diarrhea and vomiting. Reported symptoms resolved spontaneously within a few days. Similar results have also been obtained in post-marketing surveillance.
Founded in 2007, PaxVax is a fully integrated specialty vaccine company with a mission to protect people from infectious diseases. The company seeks financial returns through two specialty business strategies in travel and biodefense vaccines as well as social returns by providing access to its vaccines globally and by developing vaccines addressing some of the world's most lethal infectious diseases. The PaxVax portfolio includes a licensed vaccine for typhoid (Vivotif®), vaccines in clinical development for cholera, anthrax, HIV, and H5N1 (pandemic bird flu) and in research for malaria, dengue, rabies and Herpes Simplex Virus. PaxVax is headquartered in Redwood City, California and maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California, USA, and its newly acquired facility near Bern, Switzerland. More information is available at www.PaxVax.com.
For PaxVax, Inc.
Colin Sanford, 203-918-4347